Andrew Wirth
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Andrew Wirth has a total of 137 co-authors. Here are the top co-authors by number of shared publications:
- Michael MacManus
Peter MacCallum Cancer Centre
6 shared publications Daniel Roos
Department of Radiation Oncology, Royal Adelaide Hospital and School of Medicine, University of Adelaide, Adelaide, South Australia, Australia
3 shared publications- Henry Miles Prince
Sir Peter MacCallum Department of Oncology University of Melbourne Parkville Victoria Australia
3 shared publications - Belinda A. Campbell
Department of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; The Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria, Australia; Department of Clinical Pathology, University of Melbourne, Parkville, Victoria, Australia
2 shared publications Bouthaina Dabaja
Professor and Section Chief of Hematology, Department of Radiation Oncology, University of Texas MD Anderson Cancer, Director of Research, International Lymphoma Radiation Oncology Group, 1515 Holcombe Blvd, Houston, 77030
2 shared publicationsG. Ryan
2 shared publications
Latest Publications
- 1 January 2024
- Published by Springer Nature
- p. 265-284
Radiation Therapy for Relapsed and Refractory Hodgkin Lymphoma and Non-Hodgkin Lymphoma
- 1 January 2024
- Published by Springer Nature
- p. 265-284
Radiation Therapy for Relapsed and Refractory Hodgkin Lymphoma and Non-Hodgkin Lymphoma
- 1 November 2021
- Published by Oxford University Press (OUP) in British Journal of Radiology
- Vol. 94 (1127)
PET-guided treatment for personalised therapy of Hodgkin lymphoma and aggressive non-Hodgkin lymphoma
FDG-PET scanning has a central role in lymphoma staging and response assessment. There is a growing body of evidence that PET response assessment during and after initial systemic therapy can provide useful prognostic information, and PET response has an evolving role in guiding patient care. This review provides a perspective on the role of PET response assessment for individualised management of patients with the most common aggressive lymphomas, Hodgkin lymphoma and diffuse large B-cell lymphoma.
- 1 November 2021
- Published by Oxford University Press (OUP) in British Journal of Radiology
- Vol. 94 (1127)
PET-guided treatment for personalised therapy of Hodgkin lymphoma and aggressive non-Hodgkin lymphoma
FDG-PET scanning has a central role in lymphoma staging and response assessment. There is a growing body of evidence that PET response assessment during and after initial systemic therapy can provide useful prognostic information, and PET response has an evolving role in guiding patient care. This review provides a perspective on the role of PET response assessment for individualised management of patients with the most common aggressive lymphomas, Hodgkin lymphoma and diffuse large B-cell lymphoma.
- Open Access
- 1 August 2020
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 107 (5) , 909-933
Involved Site Radiation Therapy in Adult Lymphomas: An Overview of International Lymphoma Radiation Oncology Group Guidelines
- 1 August 2020
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 107 (5) , 909-933
Open AccessInvolved Site Radiation Therapy in Adult Lymphomas: An Overview of International Lymphoma Radiation Oncology Group Guidelines
- Open Access
Durable Complete Remission and Long-Term Survival in FDG-PET Staged Patients with Stage III Follicular Lymphoma, Treated with Wide-Field Radiation Therapy
Advanced-stage follicular lymphoma (FL) is generally considered incurable with conventional systemic therapies, but historic series describe long-term disease-free survival in stage III disease treated with wide-field radiation therapy (WFRT), encompassing all known disease sites. We report outcomes for patients staged with 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) and treated with CT-planned WFRT, given as either comprehensive lymphatic irradiation (CLI) or total nodal irradiation (TNI). This analysis of a prospective cohort includes PET-staged patients given curative-intent WFRT as a component of initial therapy, or as sole treatment for stage III FL. Thirty-three PET-staged patients with stage III FL received WFRT to 24–30Gy between 1999 and 2017. Fifteen patients also received planned systemic therapy (containing rituximab in 11 cases) as part of their primary treatment. At 10 years, overall survival and freedom from progression (FFP) were 100% and 75%, respectively. None of the 11 rituximab-treated patients have relapsed. Nine relapses occurred; seven patients required treatment, and all responded to salvage therapies. A single death occurred at 16 years. The principal acute toxicity was transient hematologic; one patient had residual grade two toxicity at one year. With FDG-PET staging, most patients with stage III FL experience prolonged FFP after WFRT, especially when combined with rituximab.
Open AccessDurable Complete Remission and Long-Term Survival in FDG-PET Staged Patients with Stage III Follicular Lymphoma, Treated with Wide-Field Radiation Therapy
Advanced-stage follicular lymphoma (FL) is generally considered incurable with conventional systemic therapies, but historic series describe long-term disease-free survival in stage III disease treated with wide-field radiation therapy (WFRT), encompassing all known disease sites. We report outcomes for patients staged with 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) and treated with CT-planned WFRT, given as either comprehensive lymphatic irradiation (CLI) or total nodal irradiation (TNI). This analysis of a prospective cohort includes PET-staged patients given curative-intent WFRT as a component of initial therapy, or as sole treatment for stage III FL. Thirty-three PET-staged patients with stage III FL received WFRT to 24–30Gy between 1999 and 2017. Fifteen patients also received planned systemic therapy (containing rituximab in 11 cases) as part of their primary treatment. At 10 years, overall survival and freedom from progression (FFP) were 100% and 75%, respectively. None of the 11 rituximab-treated patients have relapsed. Nine relapses occurred; seven patients required treatment, and all responded to salvage therapies. A single death occurred at 16 years. The principal acute toxicity was transient hematologic; one patient had residual grade two toxicity at one year. With FDG-PET staging, most patients with stage III FL experience prolonged FFP after WFRT, especially when combined with rituximab.
- 21 November 2019
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 61 (1) , 4-6
Ultra-low dose radiotherapy for salivary MALT lymphoma: lessons from small numbers
(2019). Ultra-low dose radiotherapy for salivary MALT lymphoma: lessons from small numbers. Leukemia & Lymphoma. Ahead of Print.
- 21 November 2019
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 61 (1) , 4-6
Ultra-low dose radiotherapy for salivary MALT lymphoma: lessons from small numbers
(2019). Ultra-low dose radiotherapy for salivary MALT lymphoma: lessons from small numbers. Leukemia & Lymphoma. Ahead of Print.
- 1 April 2019
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 103 (5) , 1158-1166
A Prospective, Multicenter Study of Involved-Field Radiation Therapy With Autologous Stem Cell Transplantation for Patients With Hodgkin Lymphoma and Aggressive Non-Hodgkin Lymphoma (ALLG HDNHL04/TROG 03.03)
- 1 April 2019
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 103 (5) , 1158-1166
A Prospective, Multicenter Study of Involved-Field Radiation Therapy With Autologous Stem Cell Transplantation for Patients With Hodgkin Lymphoma and Aggressive Non-Hodgkin Lymphoma (ALLG HDNHL04/TROG 03.03)
- 1 October 2017
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 99 (2) , S180
Omission of Cardiophrenic Lymph Nodes in the Treatment of Patients with Hodgkin Lymphoma Using Modified Involved Site Radiation Therapy: Lower Toxicity with No Added Failure
- 1 October 2017
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 99 (2) , S180
Omission of Cardiophrenic Lymph Nodes in the Treatment of Patients with Hodgkin Lymphoma Using Modified Involved Site Radiation Therapy: Lower Toxicity with No Added Failure
- 11 August 2016
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 57 (11) , 2487-8
Optimizing treatment for nasal NK T-cell lymphoma.
- 11 August 2016
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 57 (11) , 2487-8
Optimizing treatment for nasal NK T-cell lymphoma.